GELS Gelteq Ltd IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1920092 · Reporting currency AUD · Fiscal year ends 06/30
Financial factors as of 2025-06-30 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-06-30 · AUD | FY20242024-06-30 · AUD |
|---|---|---|
| Income statement | ||
| Revenue | 165,645 | — |
| Cost of revenue | 115,397 | — |
| Gross profit | 50,248 | — |
| R&D expense | 628,606 | 276,057 |
| Operating income | -5.50M | -2.95M |
| Interest expense | 1.92M | 599,494 |
| Pretax income | -6.65M | -3.55M |
| Net income | -$6.65MUSD | -3.55M |
| EBITDA | -4.27M | -1.73M |
| EPS (basic) | -0.72 | -0.44 |
| EPS (diluted) | -0.72 | -0.44 |
| Balance sheet | ||
| Cash & equivalents | 344,648 | 24,522 |
| Receivables | 459,724 | 183,005 |
| Current assets | 1.51M | 303,227 |
| PP&E, netmay include right-of-use assets (IFRS) | 15,907 | 16,642 |
| Intangibles | 19.86M | 20.44M |
| Total assets | 21.48M | 20.76M |
| Current liabilities | 5.63M | 3.87M |
| Short-term debt | 4.20M | 2.08M |
| Long-term debt | 13,550 | 1.76M |
| Total debt | 4.22M | 3.84M |
| Total liabilities | 5.67M | 5.65M |
| Shareholders' equity | 15.80M | 15.11M |
| Net debt | 3.87M | 3.82M |
| Cash flow statement | ||
| Operating cash flow | -5.52M | -1.07M |
| Capital expenditure | 3,117 | 3,149 |
| Free cash flow | -5.52M | -1.07M |
| Investing cash flow | -736,839 | -148,170 |
| Financing cash flow | 6.45M | 843,939 |
| Depreciation & amortization | 1.22M | 1.21M |
Free plan shows the latest 2 periods; Pro shows all 3 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.